FDA APPROVES TEVA'S GENERIC DESFERAL

Teva Pharmaceutical has announced that the FDA has granted approval for the company's abbreviated new drug application for deferoxamine mesylate for injection, in 500 mg vials and 2 g vials.

Deferoxamine mesylate for injection is the generic equivalent of Novartis' Desferal for injection, a product indicated for acute treatment of iron intoxication and chronic iron overload due to transfusion-dependent anemias.